SARASOTA, Fla., May 7, 2014 (GLOBE NEWSWIRE) -- Caribbean International Holdings (Pink Sheets:CIHN) through its subsidiary, Regenerative BioScience, Inc., ("RBS") today announced that a noted member of its Advisory Board and a scientific advisor for Regenerative Biosciences, Rafael Gonzalez, Ph.D. has been conducting negotiations on the Company's behalf with a California based "stem cell banking" company.
Dr. Gonzalez stated: "We are now in collaborative talks with a new California based stem cell banking company with years of research in the stem cell field called TheBioBox. They will store adult stem cells (bone marrow and fat) for Regenerative Biosciences patients for future use. I am particularly excited about arranging a "marriage" between RBS and this new company as it will allow us to offer "cutting edge services" to our patients. This is important because stem cells age just as we do and the younger you are when you harvest and store them, the greater the possibilities. Researchers have found that by replacing aging cells with younger ones, we may be able to stop or slow down the progression of age related diseases."
Dr. Gonzalez went on to say: "Storing your stem cells for future use is of paramount importance. It may possibly buy you time and an improved quality of life when needed."
Steven Swank, Chairman and CEO of Caribbean International Holdings, stated, "When we added Dr. Gonzales to our Advisory Board it was in part because of his connection in the overall field of stem cell research. His position as a Director at a new cryopreservation company, TheBioBox, which stores adult cells for future use, gave us an advantage to enter into a relationship with them."
Dr. Gonzalez is responsible for the development of clinical stem cell applications for several disease/trauma states for DaVinci Biosciences, LLC. Dr. Gonzalez is responsible for the design and execution of all pre-clinical and clinical experiments involving adult (bone marrow, menstrual blood, adipose) and pre-natal stem cells (neural, bone marrow, liver, gonadal). He also manages research and development personnel in accordance with company development milestones. Dr. Gonzalez also leads the biological tool based affiliate company DV Biologics which markets cells and cell based products for research and drug screening. He is a Director of TheBioBox.
The Company had previously announced that on May 15th to the 17th, Dr. Rafael Gonzalez, will be a guest speaker at the 22nd Annual World Congress on ANTI-AGING, REGENERATIVE & AESTHETIC MEDICINE, in Orlando, Florida.
About The Company:
Caribbean International Holdings, Inc. is a holding company for Regenerative Bio Science, Inc. ("RBSI"). The Company subsidiary RBSI is focused on helping individuals protect and ensure their future quality of life through Adult Stem Cell Incubation and the practice of regenerative medicine in the United States and the Dominican Republic. RBSI's mission is not only to allow patients to store their Stem Cells for future use, but also perform patient funded stem cell therapies for degenerative diseases such as MS, Arthritis, Degenerative Heart Diseases, Diabetes and a host of experimental therapies in the brain trauma disease sector including CTE. The goal is to become a global leader in establishing protocols that can be patented and utilized to heal patients around the world.
Adult stem cells work as the repairmen of the body by replenishing and regenerating damaged tissues and cells. Certain conditions have shown marked improvement when treated with adult stem cells taken from the patient's own body. Regenerative BioScience is a revolution in healthcare using a patient's own adult stem cells.
For more information go to: http://www.regenerativebioscience.com/index.html
About: Rafael Gonzalez, Ph.D.
Dr. Gonzalez has expertise in degenerative disorders involving the spinal cord and has extensive experience in stem cell culture and biology from human embryonic, pre-natal and adult sources. Prior to joining DaVinci Biosciences, Dr. Gonzalez served as a Research Scientist at PrimeGen Biotech where he was responsible for the design and execution of experiments involving adult (bone marrow, menstrual blood, adipose) and pre-natal stem cells (neural, bone marrow, liver, gonadal) for potential clinical application. Dr. Gonzalez was also responsible for developing PrimeGen's pre-clinical stem cell/spinal cord injury model.
Dr. Gonzalez developed his thesis at the Reeve-Irvine Research Center, University of California, Irvine, under the advisory of Dr. Hans Keirstead, entitled: "The Role of the Chemokine CXCL10 in Secondary Degeneration Following Spinal Cord Injury." Pre-clinical studies conducted during this time lead by Dr. Gonzalez were aimed at reducing secondary degenerative effects. The studies conducted by Dr. Gonzalez and Dr. Keirstead precipitated the start-up of Ability Biomedical, a company that developed anti-IP10 antibody, an antibody which can be used to treat several degenerative disorders such as multiple sclerosis, rheumatoid arthritis, and SCI. Ability Biomedical was purchased by Medarex in 2007 which was purchased by Bristol-Myers Squibb that sponsors a phase II clinical trial using anti-IP10 antibody (MDX-1100). He also was involved with preclinical studies in the development of the use of human embryonic stem cells into spinal cord injury.
Dr. Gonzalez has several scientific publications in the field of stem cells, spinal cord injury and the immune system.
Dr. Gonzalez received his BS in Biological Science and his Ph.D. in Anatomy and Neurobiology from the University of California, Irvine, CA.
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available on at www.sec.gov/" rel="nofollow">http://www.sec.gov.
Investor Contact: BioScience (941) 924-9400